Nodular histogenetic type - the most significant factor for thick melanoma: implications for prevention

被引:32
作者
Bergenmar, M [1 ]
Ringborg, U [1 ]
Brahme, EM [1 ]
Brandberg, Y [1 ]
机构
[1] Karolinska Hosp, Dept Oncol, S-17176 Stockholm, Sweden
关键词
gender differences; nodular melanoma; prevention; symptoms; tumour site; tumour thickness;
D O I
10.1097/00008390-199810000-00004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour thickness is the most important prognostic factor in malignant melanoma. To reduce the melanoma-related mortality, factors related to the presentation of thick melanoma have to be identified. Three samples of melanoma patients (n = 694) were studied for this purpose. Histogenetic type was the only factor which differentiated between 'thin' (less than or equal to 0.8 mm) and 'thick' (> 2.0 mm) lesions. During a 10-year period only 3% of the nodular lesions were 'thin' at diagnosis. Differences in knowledge about melanoma or the location of the lesion (either 'easy' or 'difficult' for the patient to observe) did not explain differences in tumour thickness. The most common tumour site irrespective of histogenetic type and gender was 'back of the trunk'. 'Increase in diameter' and 'bleeding' were the symptoms most frequently reported by patients with 'thick' melanoma. 'Thick' lesions were diagnosed in older age groups and in men to a greater extent. Considering these results, melanoma prevention should also be targeted to older age groups and attention should be paid to symptoms such as 'increase in diameter' even in the absence of other characteristic symptoms of melanoma. An increased proportion of nodular melanoma diagnosed as 'thin' lesions can be interpreted as a step forward in secondary prevention. (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:403 / 411
页数:9
相关论文
共 23 条
  • [1] Balch CM, 1985, CUTANEOUS MELANOMA C, P321
  • [2] BRAHME EM, 1994, CANCER, V73, P2324
  • [3] Perceived susceptibility to and knowledge of malignant melanoma: Screening participants vs the general population
    Brandberg, Y
    Bolund, C
    Michelson, H
    ManssonBrahme, E
    Ringborg, U
    Sjoden, PO
    [J]. PREVENTIVE MEDICINE, 1996, 25 (02) : 170 - 177
  • [4] INFORMATION TO PATIENTS WITH MALIGNANT-MELANOMA - A RANDOMIZED GROUP-STUDY
    BRANDBERG, Y
    BERGENMAR, M
    BOLUND, C
    MICHELSON, H
    MANSSONBRAHME, E
    RINGBORG, U
    SJODEN, PO
    [J]. PATIENT EDUCATION AND COUNSELING, 1994, 23 (02) : 97 - 105
  • [5] BRANDBERG Y, 1998, IN PRESS EUR J CANC
  • [7] REASONS FOR POOR PROGNOSIS IN BRITISH PATIENTS WITH CUTANEOUS MALIGNANT-MELANOMA
    DOHERTY, VR
    MACKIE, RM
    [J]. BRITISH MEDICAL JOURNAL, 1986, 292 (6526) : 987 - 989
  • [8] GROB JJ, 1997, MELANOMA RES S1, V7, P61
  • [9] Examination of the ability of people to identify early changes of melanoma in computer-altered pigmented skin lesions
    Hanrahan, PF
    Hersey, P
    Menzies, SW
    Watson, AB
    DEste, CA
    [J]. ARCHIVES OF DERMATOLOGY, 1997, 133 (03) : 301 - 311
  • [10] FACTORS RELATED TO THE PRESENTATION OF PATIENTS WITH THICK PRIMARY MELANOMAS
    HERSEY, P
    SILLAR, RW
    HOWE, CG
    BURTON, RC
    DARBAR, SV
    FOSTER, HM
    COLLINS, SM
    BRADLEY, DE
    OWENS, D
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1991, 154 (09) : 583 - 587